PharmacyCodes



Ridogrelum [INN-Latin] en es it fr

Ridogrelum [INN-Latin] Brand names, Ridogrelum [INN-Latin] Analogs

Ridogrelum [INN-Latin] Brand Names Mixture

  • No information avaliable

Ridogrelum [INN-Latin] Chemical_Formula

C18H17F3N2O3

Ridogrelum [INN-Latin] RX_link

No information avaliable

Ridogrelum [INN-Latin] fda sheet

Ridogrelum [INN-Latin] msds (material safety sheet)

Ridogrelum [INN-Latin] Synthesis Reference

No information avaliable

Ridogrelum [INN-Latin] Molecular Weight

366.334 g/mol

Ridogrelum [INN-Latin] Melting Point

No information avaliable

Ridogrelum [INN-Latin] H2O Solubility

No information avaliable

Ridogrelum [INN-Latin] State

Solid

Ridogrelum [INN-Latin] LogP

No information avaliable

Ridogrelum [INN-Latin] Dosage Forms

Tablets

Ridogrelum [INN-Latin] Indication

Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.

Ridogrelum [INN-Latin] Pharmacology

Ridogrel, a combined thromboxane synthase inhibitor and receptor antagonist, is used with streptokinase as an adjunctive therapy to reduce the formation and size of blood clots. Blood clots can cause ischemic cardiac events (heart attacks). Ridogrel has the dual property of inhibiting the synthesis of thromboxane and blocking the receptors of thromboxane/prostaglandin/endoperoxides. It has been shown to accelerate the speed of recanalization and to delay or prevent reocclusion during systemic thrombolysis with tissue plasminogen activator (streptokinase). Ridogrel is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis in patients suffering from acute myocardial infarction. While aspirin inhibits cyclooxygenase, the enzyme responsible for producing thromboxane, ridogrel inhibits thromboxane synthesis directly. A recent comparison between aspirin and ridogrel in as adjunct to thrombolysis in patients with acute myocardial infarction demonstrated that ridogrel is not superior to aspirin in enhancing the fibrinolytic efficacy of streptokinase but might be more effective in preventing new ischemic events. Clinical experience with this drug is still relatively limited.

Ridogrelum [INN-Latin] Absorption

Rapidly absorbed after oral administration (30-60 min)

Ridogrelum [INN-Latin] side effects and Toxicity

No information avaliable

Ridogrelum [INN-Latin] Patient Information

No information avaliable

Ridogrelum [INN-Latin] Organisms Affected

Humans and other mammals